Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14585063 | 1.00 | PIK3CD (0.34) | PIK3CDCA1CA2CA4KMT2A | |
| SCHEMBL15468305 | 0.90 | CA1 (0.39) | PIK3CDCA1CA2CA4KMT2A | |
| SCHEMBL15468302 | 0.90 | MAPK1 (0.36) | PIK3CDCA1CA2CA4CHRM2 | |
| SCHEMBL15468310 | 0.84 | CA1 (0.32) | CA1CA2CA4KMT2A | |
| SCHEMBL17577746 | 0.82 | PKM (0.31) | PIK3CDPKMALDH1A1POLB | |
| SCHEMBL12053484 | 0.78 | CYP3A4 (0.38) | — | |
| SCHEMBL12771380 | 0.75 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL12311712 | 0.75 | — | — | |
| SCHEMBL12771389 | 0.75 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL12033659 | 0.74 | XIAP (0.32) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616808-B1 | PROLYL ENDOPEPTIDASE PROBES | STANFORD RES INST INT (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2616808-B1 | PROLYL ENDOPEPTIDASE PROBES | STANFORD RES INST INT (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2012037044-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI INTERNATIONAL (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065103-A1 | Prolyl Endopeptidase Probes | PREP, XPNPEP1, ANPEP | PIK3CD 4414/4885CA1 1108/4885CA2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.